Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors.

Dose-limiting toxicities Pharmacokinetics & pharmacodynamics In the dose-escalation phase, after a single dose, Cmax increased approximately proportionally with dose, whereas AUC0–t and AUC0–∞ showed a trend toward greater-than-dose-proportional increases ( Figure 1A and B ), noting the variability and the limited sample size within each dose cohort.

also in 53,322 other papers